Study of ADI-PEG 20 Versus Placebo in Subjects With NASH
NCT ID: NCT05842512
Last Updated: 2025-09-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
60 participants
INTERVENTIONAL
2023-09-13
2028-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessment of the Safety and Effect of SAR425899 Versus Placebo for the Treatment of Non-alcoholic Fatty Liver Disease
NCT03437720
Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Adults With NASH
NCT05118360
Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)
NCT03912532
Ezetimibe Versus Placebo in the Treatment of Non-alcoholic Steatohepatitis
NCT01766713
Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)
NCT02443116
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
An external Data Safety and Monitoring Committee (DSMB) that consists of two hepatologists and a statistician will review the safety of the study. The DSMB will convene after 10 subjects (approximately 5 per treatment group) have completed the Week 4 assessments. The DSMB will receive all reports of serious adverse events (SAEs) and convene as needed to monitor for safety.
The primary efficacy will be assessed via the absolute change from baseline in hepatic fat fraction measured by MRI-PDFF at Week 24.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Drug: ADI-PEG 20
Dose: 36 mg/m2 given weekly Route of Administration: Intramuscular (IM)
ADI-PEG20
Treatment for NASH
Drug: Placebo
Dose: 36 mg/m2 given weekly Route of Administration: Intramuscular (IM)
Placebo
Treatment for NASH
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ADI-PEG20
Treatment for NASH
Placebo
Treatment for NASH
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Willingness to use appropriate contraceptive measures throughout study treatment and for 90 days thereafter (see Appendix A).
3. Body mass index (BMI) \> 23 kg/m2
4. Must have confirmation of ≥ 5 % liver fat content on MRI-PDFF at screening.
5. Biopsy-proven NASH confirmed by a central pathologist. Must have had a liver biopsy either during the screening period or a historical biopsy conducted within the last 6 months prior to pre-screening with fibrosis stage 1 to 4 (F score, F1-F4) and a non-alcoholic fatty liver disease (NAFLD) activity score (NAS) of ≥ 4 with at least a score of 1 in each of the following NAS components:
1. Steatosis (scored 0 to 3),
2. Ballooning degeneration (scored 0 to 2), and
3. Lobular inflammation (scored 0 to 3).
6. Must have no evidence of worsening of ALT and AST (within 50%) measurements within 2 months prior to screening (-8 weeks) visits.
7. Screening laboratory parameters, as determined by the central laboratory:
1. Estimated glomerular filtration rate (eGFR) ≥ 60 mL/min, as calculated by the Cockcroft- Gault equation;
2. HbA1c ≤ 9.5% (or serum fructosamine ≤ 381 μmol if HbA1c is unable to be resulted);
3. Hemoglobin ≥ 11 g/dL;
4. INR ≤ 1.3, unless due to therapeutic anticoagulation;
5. Direct bilirubin ≤ 0.5 mg/dL;
6. Total bilirubin ≤ 1.3 x upper limit of normal (ULN), unless due to an alternate etiology such as Gilbert's syndrome or hemolytic anemia;
7. Creatinine kinase \< 3 x ULN;
8. Platelet count ≥ 150,000/μL;
9. Serum triglyceride level ≤ 500 mg/dL;
10. ALT \< 6 x ULN;
11. AST \< 6 x ULN;
12. ALP \< 2 x ULN.
8. FibroScan® measurement \> 7.0 kPa and \< 20.0 kPa.
9. Subjects on non-insulin dependent diabetic, weight loss, or lipid-modifying medication(s) must be on stable dose(s) for at least 3 months prior to the diagnostic liver biopsy through randomization.
10. Subjects on vitamin E and pioglitazone must maintain a stable dosage before the diagnostic liver biopsy and during the study period.
Exclusion Criteria
2. Type 1 and insulin-dependent Type 2 diabetes.
3. Poorly controlled hypertension (blood pressure \[BP\] \> 160/100 mmHg).
4. Prior history of decompensated liver disease including ascites, hepatic encephalopathy (HE), or variceal bleeding.
5. Chronic hepatitis B virus (HBV) infection (hepatitis B surface antigen \[HBsAg\] positive.
6. Chronic hepatitis C virus (HCV) infection (HCV antibody \[Ab\] and HCV ribonucleic acid \[RNA\] positive). Subjects cured of HCV infection less than 1 year prior (based on date of RNA polymerase chain reaction \[PCR\] negative confirmation following conclusion of treatment) to the screening visit are not eligible.
7. Prior or planned (during the study period) bariatric surgery (e.g., gastroplasty, roux-en-Y gastric bypass), surgery reversal or removal of intragastric balloon \> 2 years prior to enrollment would be eligible.
8. Other causes of liver disease based on medical history and/or centralized review of liver histology, including but not limited to alcoholic liver disease, autoimmune disorders (e.g., primary biliary cholangitis \[PBC\], primary sclerosing cholangitis \[PSC\], autoimmune hepatitis), drug-induced hepatotoxicity, Wilson disease, clinically significant iron overload, or alpha-1-antitrypsin deficiency requiring treatment.
9. History of liver transplantation.
10. Subjects with primary cancer, including co-existent second malignancy, with the exception of primary solid tumor with no known active disease present in the opinion of the Investigator which will not affect subject outcome in the setting of current diagnosis.
11. Alcohol intake above an average limit of 2 drinks per day for women and 3 drinks per day for men. An alcoholic drink is defined as 12 ounces of regular beer, which is usually about 5% alcohol, 5 ounces of wine, which is typically about 12% alcohol, and 1.5 ounces of distilled spirits, which is about 40% alcohol.
12. Human immunodeficiency virus (HIV) infection.
13. Unstable cardiovascular disease in the 6 months prior to screening.
14. Life expectancy less than 2 years.
15. Use of any investigational medication within 30 days or within 5 half-lives of the investigational medication, whichever is longer, prior to screening and throughout the study is prohibited.
16. Subjects with a history of (12 months prior to baseline) or current use of prescription drugs associated with liver steatosis (e.g., methotrexate, amiodarone, high-dose estrogen, tamoxifen, systemic steroids, anabolic steroids, valproic acid) should be excluded. However, subjects currently using silymarin should maintain their current dosage throughout the trial period.
17. Contraindication of magnetic resonance imaging. These include but are not limited to devices or metal foreign bodies, such as Pacemaker, defibrillator or wires other than sternal wires, metallic foreign body in the eye, "triggerfish" contact lens, gastric reflux device, and insulin pumps.
18. MELD score \>12
19. Subjects with esophageal or gastric varices with recent bleeding episodes (within 1 year).
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Polaris Group
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John S Bomalaski
Role: STUDY_DIRECTOR
Polaris Group
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ditmanson Medical Foundation Chiayi Christian Hospital；Chiayi Christian Hospital (CYCH)
Chiayi City, Taiwan, Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital(KMUH)
Kaohsiung, Taiwan, Taiwan
E-Da Hospital (EDH)
Kaohsiung, Taiwan, Taiwan
Chang Gung Medical Foundation-Kaohsiung (CGMF-KS)
Kaohsiung, Taiwan, Taiwan
Chang Gung Medical Foundation-Keelung (CGMF-KL)
Keelung, Taiwan, Taiwan
National Cheng Kung University Hospital (NCKUH)
Tainan City, Taiwan, Taiwan
National Taiwan University Hospital (NTUH)
Taipei, Taiwan, Taiwan
Taipei Veterans General Hospital (TPVGH)
Taipei, Taiwan, Taiwan
Fu Jen Catholic University Hospital (FJCUH)
Taipei, Taiwan, Taiwan
Chang Gung Medical Foundation-Linkou (CGMF-LK)
Taoyuan District, Taiwan, Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
POLARIS2023-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.